



EFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of

VENKITARAMAN et al.

Atty. Ref.: 620-363

Serial No. 10/531,242

Group: 1656

Filed: April 14, 2005

Examiner: Unknown

For: RAD51-BRC REPEAT CRYSTALS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

November 3, 2006

Sir:

INFORMATION DISCLOSURE STATEMENT

1. **PTO-1449 Pursuant to 37 CFR 1.97(b)**
[within 3 months of filing or prior to 1st Office Action on the merits] **N/C**

2.(a) **Statement Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **N/C**

2 .(b) **Fee Payment Pursuant to 37 CFR 1.97(c)**
[before Final Office Action or Allowance (requires Rule 97(e)
Statement or Rule 17(p) fee)] **\$180.00**

3. **Pursuant to 37 CFR 1.97(d)**
[after Final Office Action or Allowance (requires Rule 97(e)
Statement and Rule 17(p) fee), but before final fee payment] **\$180.00**

The following are submitted in the above-identified application in compliance with 37 C.F.R. §§ 1.97 and 1.98:

4. A list of documents on Form PTO-1449 together with copies of each identified document and a translation or a concise explanation of each non-English language document (such as a Search Report) is enclosed herewith.

This paper is submitted in accordance with:

5. 37 CFR 1.97(b): [within 3 months of filing or prior to 1st Office Action]

6. 37 CFR 1.97(c): [before Final Office Action or Allowance, whichever is earlier]; and

a) The required Statement made in item 8 below; or

b) The \$180.00 fee specified in 37 CFR §1.17(p) for submission of this Information Disclosure Statement is authorized in item 9 below.

7. 37 CFR §1.97(d): [after Final Office Action or Allowance (requires Rule 97(e) Statement and Rule 17(p) fee), but before final fee payment]; and

a) The fee (\$180.00) required by 37 CFR §1.17(p) is submitted herewith; and

b) The required Statement is stated in item 8 below.

8. Statement under 37 CFR 1.97(e)

a) The undersigned attorney of record hereby certifies under 37 C.F.R. §1.97(e) that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement (each item contained in this IDS was the first citation of that item by a foreign patent office in a counterpart foreign application which occurred no more than three months prior to the filing of this IDS); or

b) No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement, after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

9. Please charge all deficiency fees associated with the submission of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 14-1140. An original and one (1) copy of this document are enclosed.

Respectfully submitted,
NIXON & VANDERHYE P.C.


By: _____



B. J. Sadoff

Reg. No. 36,663

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100



INFORMATION DISCLOSURE CITATION		ATTY. DOCKET NO.	SERIAL NO.
		620-363	10/531,242
		APPLICANT	
		VENKITARAMAN et al.	
		FILING DATE	GROUP
		April 14, 2005	1656
(Use several sheets if necessary)			

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Ariza et al, Nucleic Acids Research, 2005, Vol. 33, No. 5, pp 1465-1473
	Bork et al, Nature Genetics, Vol. 13, May 1996, pp 22-23
	Conway et al, Nature Structural & Molecular Biology, Vol. 11, No. 8, August 2004, pp 791-796
	Story et al, Nature, Vol. 355, January 23, 1992, pp 374-376
	Wu et al, Molecular Cell, Vol. 15, August 13, 2004, pp 423-435
	Wu et al, The Journal of Biological Chemistry, Vol. 280, No. 1, January 7, 2005, pp 722-728
	Wu et al, "Crystal structure of an ATPase-active form of Rad51 homolog from <i>Methanococcus voltae</i> : insights into potassium-dependence" JBC Papers in Press, Published on November 10, 2004 as Manuscript M411093200
	Qian et al, Biochemistry 2005, Vol. 44, pp 13753-13761
	Spies et al, Molecular Cell 21, February 17, 2006, pp 573-580
	Story et al, Nature, Vol. 355, January 23, 1992, pp 318-325
	Galkin et al, Structure 14, June 2006, pp 982-992
	Masson et al, Genes & Dev. 2001, 15:3296-3307
	Matsuo et al, FEBS Journal 273 (2006) 3148-3159

*Examiner _____ Date Considered _____

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)